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Background
S/GSK1349572 is a new integrase inhibitor (INI) with
in-vitro activity against INI-resistant HIV. Before dos-
ing a large number of subjects in pivotal clinical trials,
in-vitro findings were validated in a pilot clinical study
(ING112961). At the outset of the study, the degree of
susceptibility at which the drug no longer provides
benefit was unknown. Planned enrollment for this
study was 30 raltegravir (RAL)-resistant patients,
incorporating a broad range of in-vitro susceptibility to
S/GSK1349572. The clinical team developed novel
stopping guidelines to minimise risk to study
participants.
Methods
“Unacceptable” response rates were elicited for key
numbers of recruited subjects (e.g. 5, 20, 30). These
rates were translated statistically into a level of evidence
for unacceptable efficacy, measured as a likelihood ratio
(LR). The LR defined a stopping boundary. This bound-
ary was defined for every assessment of response and
was tested after each patient’s results were observed.
Results
LR stopping guidelines are shown in Table 1 and com-
pared with the rule “stop for >70% failures”.Af i x e d
70% failure rate threshold does not allow for accumulat-
ing evidence. LR thresholds stop for lower rates of fail-
ure as more data are collected.
At Day 11, 21/27 (78%) of subjects with resistance to
raltegravir and elvitegravir showed a virologic response.
However, five of the six failures were from the nine sub-
jects enrolled with decreased susceptibility to
GSK1349572. The failure rate in this group (5/9) met
the definition of “strong evidence of non-response”
according to the LR thresholds and so enrollment into
this group was halted early.
Conclusions
Monitoring response in a patient enables best treatment
for that individual. In trials of new treatments, deter-
mining the best option for the next patient requires
interpretation of accumulating data in population-level
monitoring. This challenging task requires a combina-
tion of clinical insight and formal quantification of evi-
dence. This case study shows that likelihood ratio
thresholds define “strong evidence” of non-response and
are suitable for constant monitoring. This approach
enables additional safety checks for the best treatment
for subjects when a new treatment has accumulated
only limited data.
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Table 1 Number of observed treatment failures that would stop the study
Number of patients observed 4 10 16 20 26 30
70% failure stopping threshold 3 7 12 14 19 21
LR stopping threshold 4 (100%) 5 (50%) 7 (44%) 8 (40%) 9 (35%) 10 (33%)
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